Grifols’ GigaGen partners with NCI to advance GIGA-564

GigaGen, a subsidiary of Grifols, announced that it has signed an agreement with the National Cancer Institute, NCI, part of the National Institutes of Health, to advance development of the company’s differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564. This Cooperative Research and Development Agreement enables further preclinical and clinical studies to assess GIGA-564’s potential across various tumor types, including the first in-human Phase 1 clinical trial for the drug candidate in advanced solid tumors. “We are proud to receive the NCI’s support and partner with their esteemed clinical research team to drive the GIGA-564 program forward,” said Carter Keller, senior vice president of Grifols and head of GigaGen. “GIGA-564 represents a new approach to designing anti-CTLA-4 agents with potential not only to enhance anti-tumor activity but also to mitigate immune-related toxicities typically associated with first generation anti-CTLA-4 therapies. We look forward to continuing to demonstrate its potential in a clinical setting as we plan to file the IND application for our first Phase 1 clinical trial in advanced solid tumors before the end of 2023.”